Early antithrombotic therapy is safe and effective in patients with blunt cerebrovascular injury and solid organ injury or traumatic brain injury

2016 ◽  
Vol 81 (1) ◽  
pp. 173-177 ◽  
Author(s):  
Charles P. Shahan ◽  
Louis J. Magnotti ◽  
Paul B. McBeth ◽  
Jordan A. Weinberg ◽  
Martin A. Croce ◽  
...  

2017 ◽  
Vol 8 (1) ◽  
pp. 76-78
Author(s):  
Dewan Shamsul Asif ◽  
Sharif Mohammad Ridwan ◽  
AM Rejaus Satter ◽  
Samson SK

Traumatic brain injury (TBI) is common in our country. In our daily practice we are successfully managing TBI. But in some cases patient clinical conditions do not correlate with neuroimaging specially CT scan of brain. These injuries are generally missed due to lack of awareness, paucity of findings in the initial CT brain, and in some cases due to delayed clinical manifestation. For more effective and appropriate management especially blunt cerebrovascular injury we are reporting this. Moreover in RTA poly trauma make our choice of treatment more difficult but rational approach can safe a patient as did in our case.Anwer Khan Modern Medical College Journal Vol. 8, No. 1: Jan 2017, P 76-78



2017 ◽  
Vol 83 (6) ◽  
pp. 527-535 ◽  
Author(s):  
Darwin Ang ◽  
Stan Kurek ◽  
Mark Mckenney ◽  
Scott Norwood ◽  
Brian Kimbrell ◽  
...  

Outpatient anticoagulation in the geriatric trauma patient is a challenging clinical problem. The aim of this study is to determine clinical outcomes associated with class of preinjury anticoagulants (PA) used by this population. This is a multicenter retrospective cohort study among four Level II trauma centers. A total of 1642 patients were evaluated; 684 patients were on anticoagulation and 958 patients were not. Patients on PA were compared with those who were not. Drug classes were divided into thromboxane A2 inhibitors, vitamin K factor-dependent inhibitors, antithrombin III activation, platelet P2Y12 inhibitors, and thrombin inhibitors. Multivariate regression was used to adjust for age, gender, race, mechanism of injury, and Injury Severity Score. No single or combination of anticoagulation agents had a significant association with mortality; however, there were positive trends toward increased mortality were noted for all antiplatelet groups involving thromboxane A2 inhibitors and platelet P2Y12 inhibitors classes. The likelihood of complications was significantly higher with platelet P2Y12 inhibitors adjusted odds ratio (aOR) 2.39 [95% confidence interval (CI) 1.32, 4.3]. The likelihood of blood transfusion was increased with vitamin K inhibitors aOR 2.89 (95% CI 1.3, 6.5), P2Y12 inhibitors aOR 2.76 (95% CI 1.12, 6.76), and combined thromboxane A2 and P2Y12 inhibitors aOR 2.89 (95% CI 1.13, 7.46). P2Y12 inhibitors were also more likely associated with traumatic brain injury aOR 2.16 (95% CI 1.01, 4.6). All classes of PA were associated with solid organ injury. There were no significant differences in the use of antiplatelet agents between patients with major indications for PA and those without major indications. Geriatric trauma patients on outpatient anticoagulants have a higher likelihood of developing complications, packed red blood cell transfusions, traumatic brain injury, and solid organ injury. Attention should be paid to patients on platelet P2Y12 inhibitors, vitamin K inhibitors, and thromboxane A2 inhibitor agents combined with platelet P2Y12 inhibitors. Opportunities exist to address the use of antiplatelet agents among patients without major indications to improve patient outcomes.



2021 ◽  
Vol 12 (8) ◽  
Author(s):  
Li Ning ◽  
Xiong Rui ◽  
Wang Bo ◽  
Geng Qing

AbstractHistone deacetylase 3 (HDAC3) plays a crucial role in chromatin remodeling, which, in turn, regulates gene transcription. Hence, HDAC3 has been implicated in various diseases, including ischemic injury, fibrosis, neurodegeneration, infections, and inflammatory conditions. In addition, HDAC3 plays vital roles under physiological conditions by regulating circadian rhythms, metabolism, and development. In this review, we summarize the current knowledge of the physiological functions of HDAC3 and its role in organ injury. We also discuss the therapeutic value of HDAC3 in various diseases.





Author(s):  
Makoto Aoki ◽  
Toshikazu Abe ◽  
Shuichi Hagiwara ◽  
Daizoh Saitoh ◽  
Kiyohiro Oshima




Sign in / Sign up

Export Citation Format

Share Document